Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Argus Research Maintains Buy on CVS Health, Lowers Price Target to $80

Author: Benzinga Newsdesk | May 08, 2024 12:00pm
Argus Research analyst Chris Graja maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $100 to $80.

Posted In: CVS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist